Literature DB >> 8543072

Management of strabismus due to orbital myositis.

D A Bessant1, J P Lee.   

Abstract

We report on 5 consecutive patients seen at the botulinum toxin clinic at Moorfields Eye Hospital with an ocular motility disorder secondary to orbital myositis. CT scans demonstrated involvement of one or both of the medial recti in the inflammatory process in all 5 patients. In addition 1 patient had involvement of both the lateral recti and the right superior rectus. Two patients had been treated with oral steroids, 3 with non-steroidal anti-inflammatory agents, and 1 with orbital radiotherapy. Prior to toxin injection 3 patients had an esotropia (ranging from 4 delta to 30 delta) and two an exotropia (52 delta and 85 delta). A vertical imbalance was present in 3, and all 5 patients had symptomatic diplopia. A total of six injections were given to 5 patients, 2 of whom later went on to have surgery. Toxin injection reduced the angle of the deviation to less than 10 delta in 4 patients, all of whom are now asymptomatic. The fifth patient has persistent diplopia despite two operations to correct a large exotropia. We discuss the role of botulinum toxin and surgery in the management of strabismus due to orbital myositis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8543072     DOI: 10.1038/eye.1995.139

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  3 in total

Review 1.  "Orbiting around" the orbital myositis: clinical features, differential diagnosis and therapy.

Authors:  F Montagnese; S Wenninger; B Schoser
Journal:  J Neurol       Date:  2015-10-17       Impact factor: 4.849

2.  Botulinum toxin for treatment of restrictive strabismus.

Authors:  Pilar S Merino; Rebeca E Vera; Laura G Mariñas; Pilar S Gómez de Liaño; Jose V Escribano
Journal:  J Optom       Date:  2016-10-19

3.  Medical and Surgical Treatment in Pediatric Orbital Myositis Associated with Coxsackie Virus.

Authors:  Pedro Gil; João Gil; Catarina Paiva; Guilherme Castela; Rui Castela
Journal:  Case Rep Ophthalmol Med       Date:  2015-10-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.